Heart failure and tachycardiomyopathy in a patient taking ibrutinib: a novel tyrosine kinase inhibitor.

被引：0

作者：

Codina, M. ^{[1
]}

Ramirez-Escudero, G. ^{[2
]}

Garcia Ibarrondo, N. ^{[2
]}

Manzanal Rey, A. ^{[2
]}

Bravo Martinez, I. ^{[3
]}

Aurrekoetxea Bajeneta, G. ^{[3
]}

Mendoza Cuartero, P. ^{[3
]}

Asla Ormaza, C. ^{[3
]}

Castellano Alcalde, M. ^{[3
]}

Uriarte Elguezabal, J. A. ^{[4
]}

Marquez Navarro, J. A. ^{[4
]}

De Bourio Uriarte, R. Martinez ^{[5
]}

Arregui Lopez, A. ^{[6
]}

Arcocha Torres, M. F. ^{[7
]}

Ruiz Gomez, L. ^{[2
]}

机构：

[1] Hosp Basurto, Noninvas Cardiac Imaging Lab, Cardiooncol, Bilbao, Spain

[2] Hosp Basurto, Noninvas Cardiac Imaging Lab, Bilbao, Spain

[3] Hosp Basurto, Dept Cardiol, Bilbao, Spain

[4] Hosp Basurto, Dept Hematol, Bilbao, Spain

[5] Hosp Basurto, Cardiac Catheterizat Lab, Bilbao, Spain

[6] Hosp Basurto, Cardiol Intens Care Unit, Bilbao, Spain

[7] Hosp Basurto, Dept Cardiol, Electrophysiol Lab, Bilbao, Spain

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P1210

引用

页码：303 / 303

页数：1

共 50 条

[41] A concise synthesis of a novel antiangiogenic tyrosine kinase inhibitor
Payack, JF
Vazquez, E
Matty, L
Kress, MH
McNamara, J
JOURNAL OF ORGANIC CHEMISTRY, 2005, 70 (01): : 175 - 178
[42] Design and synthesis of a novel tyrosine kinase inhibitor template
Slavish, P. Jake
Jiang, Qin
Cui, Xiaoli
Morris, Stephan W.
Webb, Thomas R.
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (09) : 3308 - 3316
[43] Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
Jin Wang
Xiaoyang Liu
Yongzhi Hong
Songtao Wang
Pin Chen
Aihua Gu
Xiaoyuan Guo
Peng Zhao
Journal of Experimental & Clinical Cancer Research, 36
[44] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Marostica, Eleonora
Sukbuntherng, Juthamas
Loury, David
de Jong, Jan
de Trixhe, Xavier Woot
Vermeulen, An
De Nicolao, Giuseppe
O'Brien, Susan
Byrd, John C.
Advani, Ranjana
McGreivy, Jesse
Poggesi, Italo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 111 - 121
[45] Ibrutinib, a Bruton's tyrosine kinase inhibitor, regulates ventricular electromechanical activities and enhances arrhythmogenesis
Liu, Chih-Min
Lin, Fong-Jhih
Chhay, Chheng
Chen, Yao-Chang
Lin, Yung-Kuo
Lu, Yen -Yu
Chan, Chao -Shun
Higa, Satoshi
Chen, Shih-Ann
Chen, Yi-Jen
EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 977
[46] Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies
Tillman, Benjamin F.
Pauff, James M.
Satyanarayana, Gowri
Talbott, Mahsa
Warner, Jeremy L.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (04) : 325 - 334
[47] Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
Zhu, Zhen
Ling, Lanlan
Qi, Lezhong
Chong, Yue
Xue, Li
ONCOTARGETS AND THERAPY, 2020, 13 : 4113 - 4122
[48] Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Patel, Viralkumar
Balakrishnan, Kumudha
Bibikova, Elena
Ayres, Mary
Keating, Michael J.
Wierda, William G.
Gandhi, Varsha
CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3734 - 3743
[49] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Eleonora Marostica
Juthamas Sukbuntherng
David Loury
Jan de Jong
Xavier Woot de Trixhe
An Vermeulen
Giuseppe De Nicolao
Susan O’Brien
John C. Byrd
Ranjana Advani
Jesse McGreivy
Italo Poggesi
Cancer Chemotherapy and Pharmacology, 2015, 75 : 111 - 121
[50] Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
Wang, Jin
Liu, Xiaoyang
Hong, Yongzhi
Wang, Songtao
Chen, Pin
Gu, Aihua
Guo, Xiaoyuan
Zhao, Peng
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36

← 1 2 3 4 5 →